Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy with No Dose Limiting Toxicity in Metastatic Pancreatic Cancer

SAN MARINO, Calif., April 21 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation announced today that Interim Analysis of an on-going Phase I/II study of Rexin-G for pancreatic cancer confirmed Rexin-G’s anti-tumor activity with no major toxicity in patients with metastatic chemotherapy-resistant pancreatic cancer.